Pulished Date August, 2019
ID: 1081
Share on
Share on

Asia Pacific Biosimilars Market Research Report – Segmented By Type, By Technology, By Application, By Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends, Forecast | 2019 – 2024

Pulished: August, 2019
ID: 1081
Pages: 145

APAC Biosimilars Market Size & Growth (2019 - 2024)

As per our analysis, the size of the Biosimilars Market in the Asia Pacific was worth USD 1.26 million in 2019 and estimated to be growing at a CAGR of 31.60%, to reach USD 4.99 million by 2024.

Biosimilars are recognized as among the healthcare industry's most significant markets. Biosimilars are seen as an accessible and economical treatment option with rising healthcare costs. Growing economies are seeing extensive development from the challenging medical therapeutic needs in the biosimilar industry. Rising GDP and healthcare sector spending and demand for an economical therapeutic solution have contributed to this market's growth. In addition, biosimilars find their use in the prevention and treatment of various chronic disorders like diabetes, cancers, cardiovascular diseases, etc. and demand for biosimilars is likely to rise in the coming years.

While Asia-Pacific is the quickest-growing market for biosimilars due to low production costs, skilled and cheap labor availability, slender regulations laid down by governments, there are however cost high for manufacturing and sophistication, and the prevalence on the market of economically priced generic drugs which has come forward as some of the biosimilars market's main constraints.

Biosimilars are a great opportunity; the market will eventually become a huge business, irrespective of a slow start. Countries like India, China, and South Korea, in the region, are providing an enticing opportunity to develop and sell medicines. In addition, these markets are generic-driven, creating a favorable incentive for the development and marketing of biosimilars. Also, the growing initiatives from the government and increasing investment in the healthcare sector in the region are providing lucrative growth opportunities for the region’s market to grow substantially. Throughout the forecast period, large profit-churning blockbuster drugs are expected to lose their patent protection in APAC, and biosimilar firms are vigilant in filing marketing rights proposals.

This research report segmented and sub-segmented the market into the following categories:

  • By Type: Protein, Insulin, Human Growth Hormones, Granulocyte Colony-stimulating Factor (G-CSF), Interferons, Recombinant Glycosylated Proteins, Erythropoietin, Monoclonal Antibodies, Follitropin, Recombinant Peptides, Glucagon and Calcitonin
  • By Technology: Mass Spectroscopy, Chromatography, Monoclonal Antibody Technology, Recombinant DNA Technology, Nuclear magnetic resonance (NMR) technology, Electrophoresis and Bioassay
  • By Application: Oncology diseases, Blood disorders, Growth hormone deficiencies, Chronic and autoimmune diseases and Others.
  • By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC

Regionally, the Asia-Pacific market is segmented into various regions namely Japan, China, India and Australia. India and China are estimated to grow the fastest. Other countries such as South Korea are also expected to record high growth over the next five years. India is one of the largest hubs for the biosimilar industry and observes a presence of over 30 leading firms that operate in the development of biosimilars, some of which include Dr Reddy’s Laboratories, Wockhardt, Lupin, Cipla, Avesthagen, Biocon, and Zydus Cadilla.

Notable companies in the APAC Biosimilars market are Sandoz International GmbH, Wockhardt Ltd, Hospira, Inc., Teva Pharmaceutical Industries Ltd. Dr. Reddy’s Laboratories, Biocon Limited, Mylan, Inc., Zydus Cadila, Celltrion Inc., Roche Diagnostics and Cipla Ltd.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Type                        

                                5.1.1 Protein     

                                5.1.2 Insulin       

                                5.1.3 Human Growth Hormones

                                5.1.4 Granulocyte Colony-stimulating Factor (G-CSF)       

                                5.1.5 Interferons             

                                5.1.6 Recombinant Glycosylated Proteins             

                                5.1.7 Erythropoietin       

                                5.1.8 Monoclonal Antibodies     

                                5.1.9 Follitropin

                                5.1.10 Recombinant Peptides    

                                5.1.11 Glucagon               

                                5.1.12 Calcitonin              

                5.2 By Technology                          

                                5.2.1 Mass Spectroscopy             

                                5.2.2 Chromatography  

                                5.2.3 Monoclonal Antibody Technology

                                5.2.4 Recombinant DNA Technology       

                                5.2.5 Nuclear magnetic resonance (NMR) technology     

                                5.2.6 Electrophoresis     

                                5.2.7 Bioassay   

                5.3 By Application                           

                                5.3.1 Oncology diseases

                                5.3.2 Blood disorders    

                                5.3.3 Growth hormone deficiencies        

                                5.3.4 Chronic and autoimmune diseases

                                5.3.5 Others      

6. Geographical Analysis                                              

                6.3 Asia-Pacific                 

                                6.1 Introduction              

                                6.2 China            

                                6.3 India              

                                6.4 Japan            

                                6.5 South Korea

                                6.6 Australia      

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Sandoz International GmbH                

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Wockhardt                 

                8.3 Hospira                        

                8.4 Teva Pharmaceutical Industries                         

                8.5 Dr. Reddy’s Laboratories                      

                8.6 Biocon                          

                8.7 Mylan                           

                8.8 Zydus Cadila                               

                8.9 Celltrion                       

                8.10 Roche Diagnostics                 

                8.11 Cipla                            

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

                                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  • Asia-Pacific Biosimilars Market By Type, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Protein Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Insulin Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Human Growth Hormones Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Granulocyte Colony-stimulating Factor (G-CSF) Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Interferons Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Recombinant Glycosylated Proteins Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Erythropoietin Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Monoclonal Antibodies Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Follitropin Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Recombinant Peptides Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Glucagon Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Calcitonin Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Biosimilars Market By Technology, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Mass Spectroscopy Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Chromatography Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Monoclonal Antibody Technology Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Recombinant DNA Technology Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Nuclear magnetic resonance (NMR) technology Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Electrophoresis Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Bioassay Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Biosimilars Market By Application, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Oncology diseases Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Blood disorders Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Growth hormone deficiencies Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Chronic and autoimmune diseases Market By Region, From 2019 - 2024 ( USD Million )
  • Asia-Pacific Others Market By Region, From 2019 - 2024 ( USD Million )
  • Japan Biosimilars Market By Type, From 2019 - 2024 ( USD Million )
  • Japan Biosimilars Market By Technology, From 2019 - 2024 ( USD Million )
  • Japan Biosimilars Market By Application, From 2019 - 2024 ( USD Million )
  • China Biosimilars Market By Type, From 2019 - 2024 ( USD Million )
  • China Biosimilars Market By Technology, From 2019 - 2024 ( USD Million )
  • China Biosimilars Market By Application, From 2019 - 2024 ( USD Million )
  • India Biosimilars Market By Type, From 2019 - 2024 ( USD Million )
  • India Biosimilars Market By Technology, From 2019 - 2024 ( USD Million )
  • India Biosimilars Market By Application, From 2019 - 2024 ( USD Million )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample